COAG

Hemab Therapeutics Holdings, Inc.

Healthcare · Biotechnology

30.80$ -5.4% vs. previous close Closing price · As of: Sep 30, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Income Statement COAG
Line item	2024	2025
Revenue	0.00	0.00
Research & Development	0.94	2.17
Selling, General & Administrative	0.20	0.38
Total Operating Expenses	1.14	2.56
Operating Income	-1.14	-2.56
Pre-Tax Income	-1.10	-2.34
Income Tax Expense	–	-0.01
Net Income	-1.10	-2.33
EBITDA	-1.13	-2.54

Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.